The Paul-Ehrlich-Institut informs - Temporary Suspension of Vaccination with COVID-19 Vaccine AstraZeneca
Following intensive consultations on the serious thrombotic events that have occurred in Germany and Europe, the Paul-Ehrlich-Institut recommends the temporary suspension of vaccinations with the COVID-19 vaccine AstraZeneca.
Compared to the status on 11 March 2021, additional cases (as of Monday, 15 March 2021) have now been reported in Germany. Analysing the new data status, the experts of the Paul-Ehrlich-Institut now see a striking accumulation of a special form of very rare cerebral vein thrombosis (sinus vein thrombosis) in connection with a deficiency of blood platelets (thrombocytopenia) and bleeding in temporal proximity to vaccinations with the COVID-19 vaccine AstraZeneca.
The data are being further analysed and evaluated by the European Medicines Agency (EMA).
Vaccinations with AstraZeneca's COVID-19 vaccine in Germany will be suspended until the EMA's evaluation is complete. Today's decision affects both initial and follow-up vaccinations.
The Paul-Ehrlich-Institut advises that individuals who have received AstraZeneca's COVID-19 vaccine and feel increasingly unwell more than four days after vaccination - for example, with severe and persistent headache or pinpoint bleeding of the skin - should seek medical treatment immediately.